Olanzapine in relapsing schizophrenia. Efficacy and serotonergic parameters

European Journal of Psychiatry

Volumn 15, Issue 2, 2001, Pages 91-100

  Mooren, R ^a   Verhoeven, W M A ^a,b   Tuinier, S ^a   Van Den Berg, Y W M M ^a   Fekkes, D ^b   Pepplinkhuizen, L ^b  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Norharman; Olanzapine; Schizophrenia; Serotonin

Indexed keywords

AMINO ACID; OLANZAPINE; SEROTONIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; NEUROTRANSMISSION; RECURRENT DISEASE; SCHIZOPHRENIA; SEROTONIN BLOOD LEVEL; WEIGHT GAIN; WELLBEING;

EID: 0035005382     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
2. Norharman changes of extracellular concentrations of dopamine in the nucleus accumbens of rats
3. Olanzapine versus placebo and haloperidol
4. Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients
5. Serotonin, schizophrenia and antipsychotic drug action
6. Structured interview for assessing perceptual anomalies (SIAPA)
7. Radioreceptor binding profile of the atypical antipsychotic olanzapine
8. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
9. Psychopathology, serotonergic parameters and sertindole; results of a preliminary study in schizophrenia
10. Abnormal metabolism of serine, methionine and taurine in transient acute polymorphic psychosis
11. Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatization with o-phthaldialdehyde
12. Amino acid studies in transient acute polymorphic psychosis
13. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double blind trial
14. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes
15. Serotonin-dopamine interaction and its relevance to schizophrenia
16. Depressive, negative and positive symptoms in schizophrenia: Reponse to different dosages of haloperidol
17. The cimetidine-induced increase in prolactin secretion in schizophrenia; effects of clozapine
18. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics
19. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms
20. Olanzapine versus haloperidol treatment in first-episode psychosis
21. Modulatory role of serotonin in neural information processing; implications for human psychopathology
22. Schizophrenia and glutamatergic transmission
23. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizopheniform disorders: Results of an international collaborative trial
24. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
25. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol
26. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
27. Aminoacids, norharman and serotonergic parameters in schizophrenia: Clinical and biochemical effects of treatment with risperidone
28. Long-term considerations after switching antipsychotics